| CPC A61K 31/47 (2013.01) [A61K 9/0048 (2013.01); A61K 47/36 (2013.01); A61K 47/38 (2013.01); A61K 47/44 (2013.01); A61K 47/547 (2017.08)] | 28 Claims |
|
1. An ophthalmologically suitable pharmaceutical composition in the form of a suspension comprising:
(1) a suspension agent component comprising at least two suspension agents, the at least two suspension agents comprising at least one ionic suspension agent present in an amount of between 0.2% and 2% by weight of the composition and if the at least one ionic suspension agent is a surfactant, the at least ionic suspension agent has an average molecular weight of at least about 1,000 Da, and (b) at least one non-ionic suspension agent present in an amount of between 0.5% and 2% by weight of the composition; and
(2) an active pharmaceutical ingredient component consisting of a fluoroquinolone antibiotic component and an anti-inflammatory component, wherein
(a) the fluoroquinolone antibiotic component comprises at least one fluoroquinolone antibiotic compound present in the composition in an amount representing 0.01% to 1% of the composition by weight; and
(b) the anti-inflammatory component comprises at least one steroid anti-inflammatory compound, wherein the anti-inflammatory component is present in the composition in an amount representing 0.1% to 5% of the composition by weight,
wherein the ratio of the anti-inflammatory component to the at least one ionic suspension agent is between 1:20 and 15:1, and further wherein the ratio of the anti-inflammatory component to a combination of the at least one ionic suspension agent and the at least one non-ionic suspension agent is 2.5:1 to 1:120 wherein the at least one fluoroquinolone antibiotic compound is moxifloxacin or gatifloxacin; further wherein the at least one steroid anti-inflammatory compound is triamcinolone, prednisolone, or loteprednol.
|